Dihydromyricetin Market Size & Share Trends, 2033

Dihydromyricetin Market Overview

The Dihydromyricetin Market size was valued at USD 339.08 million in 2024 and is expected to reach USD 496.4 million by 2033, growing at a CAGR of 4.3% from 2025 to 2033.

Dihydromyricetin (DHM), also known as ampelopsin, is a flavonoid compound extracted primarily from the plant Ampelopsis grossedentata. It has garnered significant attention due to its diverse pharmacological properties, including antioxidant, anti-inflammatory, and hepatoprotective effects. The global demand for DHM has been on the rise, driven by its applications in pharmaceuticals, functional foods, and cosmetics. In 2023, the global production of DHM was estimated at approximately 1,500 metric tons, with China accounting for over 70% of the output.

The purity levels of commercially available DHM typically range between 95% and 98%, catering to different industry requirements. The compound's solubility in water is relatively low, measured at 0.2 mg/mL at 25°C, which has prompted research into various formulation techniques to enhance its bioavailability. Notably, DHM exhibits stability in weakly acidic environments but degrades under alkaline conditions and elevated temperatures, with a 40% reduction in concentration observed after 16 days at 60°C. These physicochemical characteristics are critical considerations for manufacturers and researchers aiming to develop effective DHM-based product.

Key Findings

Driver: The increasing consumer preference for natural and plant-based health supplements is propelling the demand for dihydromyricetin.

Top Country/Region: China remains the leading producer and consumer of DHM, contributing to over 70% of the global market share.

Top Segment: The pharmaceutical and healthcare sector dominates DHM applications, utilizing its hepatoprotective and antioxidant properties.

Dihydromyricetin Market Trends

The dihydromyricetin market is experiencing significant growth, influenced by various trends across industries. In the pharmaceutical sector, DHM's potential in treating liver diseases and its neuroprotective effects have led to increased research and product development. Studies have demonstrated DHM's efficacy in mitigating alcohol-induced liver damage and its role in modulating neurotransmitter activity, making it a candidate for addressing alcohol dependence and related disorders. In the nutraceutical industry, the demand for natural antioxidants has surged, with DHM being incorporated into dietary supplements aimed at promoting liver health and overall well-being. The food and beverage sector is also exploring DHM's application in functional drinks and health-oriented products, leveraging its antioxidant properties. Moreover, the cosmetic industry is integrating DHM into skincare formulations due to its anti-aging and UV-protective effects.

Technological advancements have facilitated the development of various DHM formulations, including nanoencapsulation and liposomal delivery systems, to overcome its low water solubility and enhance bioavailability. These innovations are expanding DHM's applicability and consumer reach. Additionally, the rise of e-commerce platforms has improved product accessibility, contributing to market expansion. However, the market faces challenges such as regulatory hurdles and the need for standardized quality control measures to ensure product efficacy and safety.

Dihydromyricetin Market Dynamics

DRIVER

Rising demand for pharmaceuticals.

The pharmaceutical industry's growing focus on natural compounds has positioned dihydromyricetin as a valuable ingredient due to its hepatoprotective, antioxidant, and neuroprotective properties. Clinical studies have highlighted DHM's potential in treating liver ailments, reducing oxidative stress, and mitigating alcohol-induced damage. Its role in modulating GABA receptors suggests applications in managing anxiety and alcohol dependence. The increasing prevalence of liver diseases and the global burden of alcohol-related disorders have amplified the demand for effective, natural therapeutic agents like DHM.

RESTRAINT

Limited consumer awareness.

Despite its promising health benefits, dihydromyricetin remains relatively unknown among the general consumer base. This lack of awareness hampers market penetration, particularly in regions outside East Asia where traditional use of vine tea is prevalent. The scientific nomenclature and limited marketing efforts contribute to consumer unfamiliarity. Furthermore, the absence of widespread clinical endorsements and mainstream media coverage restricts DHM's visibility.

OPPORTUNITY

Growth in personalized medicines.

The shift towards personalized medicine offers a substantial opportunity for dihydromyricetin integration. DHM's multifaceted pharmacological profile allows for its inclusion in tailored therapeutic regimens targeting specific health conditions such as liver disorders, metabolic syndromes, and neurodegenerative diseases. Advancements in pharmacogenomics can facilitate the identification of patient populations that would benefit most from DHM-based treatments. Moreover, the development of customized DHM formulations, considering individual metabolic responses and health profiles, aligns with the personalized medicine paradigm.

CHALLENGE

Rising costs and expenditures.

The production and commercialization of dihydromyricetin face financial challenges due to high extraction costs, quality control measures, and regulatory compliance expenses. The extraction process from natural sources requires significant investment in raw materials and technological infrastructure. Ensuring consistent purity levels (typically 95% or 98%) demands rigorous quality assurance protocols, adding to operational costs. Additionally, navigating the complex regulatory landscapes across different countries involves substantial expenditures for certifications and approvals. These financial burdens can deter small and medium enterprises from entering the market and may lead to higher product prices, affecting consumer accessibility and market competitiveness.

Dihydromyricetin Market Segmentation

The dihydromyricetin market is segmented based on type and application to cater to diverse industry needs. By type, the market includes DHM with purity levels of 95%, 98%, and other specifications. By application, it spans pharmaceuticals and healthcare, food and feed additives, and other sectors such as cosmetics. This segmentation allows manufacturers to target specific market segments with tailored products, addressing varying purity requirements and application-specific formulations.

By Type

95 Purity: Dihydromyricetin with 95% purity is commonly utilized in the food and beverage industry, particularly in functional drinks and dietary supplements. Its antioxidant properties make it a valuable additive for health-oriented products. The relatively lower purity level compared to pharmaceutical-grade DHM allows for cost-effective incorporation into mass-market consumables. In 2023, the demand for 95% purity DHM accounted for approximately 40% of the total market share, reflecting its widespread application in consumer health products.
98 Purity: dihydromyricetin is primarily targeted towards the pharmaceutical and healthcare sectors. This high-purity grade is essential for clinical applications, ensuring efficacy and safety in therapeutic formulations. Pharmaceutical companies prioritize this grade for developing medications aimed at liver protection, anti-inflammatory treatments, and neuroprotective therapies. In 2023, 98% purity DHM constituted approximately 50% of the market demand, underscoring its critical role in medical applications.
Others: purity levels of dihydromyricetin, including those below 95%, are utilized in various industrial applications such as cosmetics and animal feed. In cosmetics, DHM is incorporated for its anti-aging and skin-protective properties. In animal nutrition, it serves as a feed additive to enhance health and growth performance. These applications, while niche, contribute to the diversification of DHM's market presence.

By Application

Pharma and Healthcare: sector represents the largest application segment for dihydromyricetin. Its therapeutic properties, including hepatoprotection, antioxidation, and neuroprotection, have led to its incorporation into various medicinal products. Clinical studies have validated DHM's efficacy in treating liver diseases and mitigating alcohol-induced damage, bolstering its demand in this sector. In 2023, this segment accounted for over 50% of the total DHM market consumption.
Food and Feed Additives: Dihydromyricetin's antioxidant and health-promoting properties have facilitated its use in the food industry as a functional ingredient in beverages, supplements, and health foods. In animal nutrition, DHM is added to feed to improve health outcomes and productivity. This segment has witnessed steady growth, comprising approximately 30% of the market share in 2023, driven by consumer demand for natural and health-enhancing products.
Others: Beyond pharmaceuticals and food, dihydromyricetin finds applications in cosmetics and personal care products due to its anti-aging and UV-protective effects. Its incorporation into skincare formulations addresses consumer preferences for natural and effective ingredients. Although this segment holds a smaller market share, estimated at around 20% in 2023, it presents opportunities for growth as the demand for natural cosmetics rises.

Dihydromyricetin Market Regional Outlook

The global dihydromyricetin market displays a concentrated regional distribution, with dominance by East Asian producers and emerging interest across North America, Europe, Asia-Pacific, and the Middle East & Africa. Each region exhibits unique trends based on production capabilities, regulatory frameworks, and consumer awareness regarding natural flavonoids.

North America

has emerged as a promising market for dihydromyricetin, primarily due to rising consumer demand for plant-derived supplements and hepatoprotective agents. In 2023, the U.S. accounted for over 65% of the regional market, with a notable rise in nutraceutical product launches featuring DHM as a key active ingredient. The dietary supplement segment witnessed a volume increase of over 12% from 2022 to 2023, driven by growing interest in liver detox and alcohol recovery products. The U.S. Food and Drug Administration (FDA) has not yet officially approved DHM as a drug, but several companies are conducting safety assessments to support its status as a GRAS (Generally Recognized As Safe) substance in supplements.

Europe

remains moderately active in the dihydromyricetin market, with increased emphasis on regulatory compliance and natural ingredient sourcing. Germany, France, and the United Kingdom collectively represent over 60% of Europe’s DHM consumption. In Germany, more than 40 brands introduced liver health supplements in 2023, many of which included DHM in their formulations. The EU’s stringent regulations have led to higher demand for DHM with 98% purity, and the European Pharmacopoeia is actively evaluating monograph proposals to standardize DHM.

Asia-Pacific

dominates the global dihydromyricetin market, contributing more than 70% of the total production and over 60% of total global consumption in 2023. China alone accounts for nearly 85% of global DHM extraction, with major production hubs in Shaanxi and Hunan provinces. Over 90 manufacturers operate in China, with leading firms processing more than 1,000 tons annually. Japan and South Korea are key importers in the region, integrating DHM into traditional herbal medicine and functional beverages. In South Korea, functional drinks with DHM saw a 21% sales increase in 2023 compared to 2022.

Middle East & Africa

region is an emerging market for dihydromyricetin, though current volumes remain relatively low. The UAE and South Africa are the primary entry points, accounting for over 70% of DHM imports into the region. In 2023, MEA's import volume increased by 9.3% year-on-year, mainly for use in wellness supplements and herbal teas. Rising disposable income and the growing popularity of natural health solutions have led to the establishment of new distribution channels for DHM-based products, particularly in online retail.

List of Top Dihydromyricetin Companies

Xian Sost Biotech
Wuhan Vanz Pharm
Xi'an Lyphar Biotech
Xi'an Natural Field Bio-Technique
Xian Tonking Biotech
Yongzhou Huamao Biotechnology
Xi'an Arisun ChemPharm
Xi'an Pincredit Bio-Tech
Chengdu Push Bio-technology

Xian Sost Biotech: held approximately 14.7% of the global dihydromyricetin production volume. The company operates a high-capacity GMP-certified facility in Shaanxi, processing over 1,200 metric tons of vine tea leaves annually for DHM extraction. It exports to over 35 countries and has partnerships with more than 90 supplement brands worldwide.

Xi'an Lyphar Biotech: commands an estimated 12.9% share of the global DHM market by volume. In 2023, it expanded its production line to handle 950 tons of raw vine tea annually and launched 7 new DHM formulations targeting liver health and cognitive performance. The firm also reported a 19.3% year-over-year increase in bulk export contracts.

Investment Analysis and Opportunities

The dihydromyricetin market is witnessing heightened investor interest, particularly in areas such as product formulation innovation, extraction technologies, and expanding distribution channels. In 2023, over 25 companies invested in upgrading their extraction facilities to enhance yield efficiency and maintain high purity (95% and 98%). Chinese firms led these investments, with more than ¥300 million directed toward scaling up production capacity. Several players in the nutraceutical space secured multi-year contracts with contract manufacturers to ensure consistent DHM supply for high-demand health supplements. In North America, investment in R&D surrounding DHM’s neuroprotective potential has increased significantly. As of Q4 2023, five U.S.-based biotechnology firms initiated clinical trials evaluating DHM for alcohol withdrawal syndrome and cognitive health. One biotech startup based in California raised $6.2 million in Series A funding, with a focus on developing DHM-based pharmaceuticals. These trials could establish regulatory pathways and open up new therapeutic markets.

Investment opportunities are also growing in the cosmetic sector. With DHM's anti-inflammatory and antioxidant properties proving beneficial in skincare applications, cosmetic manufacturers are launching serums and creams featuring 0.95 purity DHM. The segment saw an investment surge of 14.5% in 2023, focused primarily on Asia and Europe. On the infrastructure side, supply chain investments are being made to reduce dependency on single-source producers. In 2023, three large-scale processing plants were inaugurated in India and Vietnam to reduce logistics costs and enhance regional availability of raw DHM extract. This is critical in light of China’s concentration of production—over 85% of global DHM is still sourced from China. The global e-commerce sector has also enabled cross-border investments. In 2023, online supplement sales containing DHM increased by 31%, spurring venture capital interest in direct-to-consumer (DTC) brands. One European DTC brand raised €3.1 million for a line of liver support capsules infused with DHM and milk thistle extract.

New Product Development

The dihydromyricetin (DHM) market has become a hotbed for innovation, with manufacturers introducing novel formulations across the dietary supplement, pharmaceutical, functional beverage, and skincare sectors. In 2023 and early 2024, over 45 new DHM-infused products were launched globally, reflecting rising consumer interest in natural compounds with hepatoprotective, antioxidant, and neuroprotective properties. One of the most notable developments is the combination of DHM with other bioactive ingredients such as silymarin, curcumin, and N-acetylcysteine. In 2023, 12 new multi-ingredient liver detox capsules featuring 98% purity DHM were launched in North America. These blends were designed to enhance liver enzyme normalization, support alcohol metabolism, and reduce oxidative stress. Clinical testing on one such product demonstrated a 28% reduction in ALT and AST liver enzymes after 8 weeks of use. The functional beverage sector also saw significant product innovation. In Japan, two leading companies launched ready-to-drink (RTD) anti-hangover shots containing 300 mg of DHM per serving. These beverages target working professionals and are marketed as fast-acting liver protectants. In South Korea, a new line of sparkling drinks with 0.95 purity DHM experienced a 21.6% sales increase in Q4 2023, indicating growing acceptance in wellness-oriented drinks. In Europe, new liposomal DHM formulations have gained traction. These nano-delivery systems enhance bioavailability by up to 63% compared to standard capsules, making them more effective for neurological applications.

The Phase I trial indicated tolerability and a measurable reduction in GABA receptor overactivity, marking a breakthrough in neurotherapeutic research. The cosmetic and dermatology sector is adopting DHM for its anti-inflammatory and anti-aging effects. In 2023, three new brands launched DHM-based facial serums combining 0.98 purity DHM with hyaluronic acid and niacinamide. Clinical studies conducted by one brand revealed a 19.4% reduction in skin redness and 22% increase in elasticity after four weeks of application. Additionally, pet health is becoming an emerging segment. A Canadian company introduced DHM-laced canine supplements for liver health, especially targeting aging pets. The product contains 75 mg of DHM per chew and showed a notable improvement in liver function in 72% of test animals over a 60-day trial. Innovation in delivery formats is another trend. DHM is now available in sublingual films, effervescent powders, and liquid tinctures, offering consumers flexible intake options. In 2024, a startup in Singapore released DHM-infused herbal mouth sprays, aiming to serve customers looking for instant absorption and alcohol metabolism benefits. Overall, the pace of new product development is accelerating, fueled by technological advancements in extraction, formulation science, and delivery mechanisms. These innovations not only expand the functional scope of DHM but also drive adoption across diverse consumer segments globally.

Five Recent Developments

In early 2023, Xian Sost Biotech expanded its production capacity by commissioning a new extraction line capable of processing 600 tons of raw vine tea annually. This addition increased their total annual processing capacity to 1,800 tons, aiming to meet growing global demand for 98% purity dihydromyricetin. The facility incorporates advanced membrane filtration technology to improve yield by approximately 12%.
In mid-2023, Wuhan Vanz Pharm launched a new patented DHM extraction process that reduced solvent use by 30%, lowering environmental impact and production costs. The new process boosted DHM purity consistency from 95% to 98% and shortened production time by 15%, supporting faster product rollouts.
In late 2023, Xi'an Lyphar Biotech entered a strategic partnership with a leading North American nutraceutical distributor to supply over 200 metric tons of DHM powder annually. This contract expanded Xi'an Lyphar’s market footprint into the U.S. and Canada, representing a 25% increase in their export volume compared to 2022.
In Q1 2024, Chengdu Push Bio-technology developed an innovative DHM liposomal formulation that improved oral bioavailability by 60%. The company filed for regulatory approval in Europe and plans commercial launch in the second half of 2024, targeting cognitive health and liver support supplement markets.
In early 2024, Xi’an Natural Field Bio-Technique introduced a line of functional beverages infused with 300 mg of 0.95 purity DHM per serving. The product, launched initially in South Korea and Japan, recorded sales exceeding 25,000 units within the first three months, capitalizing on increasing consumer interest in natural anti-hangover solutions.

Report Coverage of Dihydromyricetin Market

The report on the dihydromyricetin (DHM) market offers an extensive and comprehensive analysis of the global industry landscape, capturing production, consumption, key players, and future growth drivers. It encompasses detailed segmentation by type and application, enabling stakeholders to understand the nuances of various DHM grades, including 0.95 purity, 0.98 purity, and others, as well as their use across pharma, healthcare, food and feed additives, and miscellaneous applications. The scope of the report includes granular data on production volumes, extraction technologies, and purity standards. For instance, it documents that China accounted for nearly 85% of the world’s DHM output in 2023, with Shaanxi province alone hosting over 50 large-scale processing units. The report details how 0.98 purity DHM is preferred for pharmaceutical formulations due to its enhanced bioactivity, whereas 0.95 purity variants dominate the food and beverage sectors. Key market dynamics such as drivers, restraints, opportunities, and challenges are examined with quantitative backing.

For example, rising demand for natural hepatoprotective agents has led to a 14% increase in global DHM consumption between 2022 and 2023, while regulatory hurdles in Europe and the U.S. represent significant restraints impacting market expansion. The competitive landscape is profiled thoroughly, highlighting major companies like Xian Sost Biotech and Xi’an Lyphar Biotech, which together accounted for nearly 28% of the global market share by volume in 2023. Their investment strategies, capacity expansions, and innovation pipelines are detailed to provide insights into market positioning. Regional outlooks cover North America, Europe, Asia-Pacific, and Middle East & Africa, providing volume and consumption statistics. For example, North America’s DHM import volume increased by over 12% in 2023, driven largely by U.S. nutraceutical demand, while Europe saw a 15% rise in imports from Asia, reflecting growing consumer inclination towards clean-label natural supplements. Additionally, the report delves into recent product developments, including the emergence of liposomal DHM formulations and combination products with silymarin and curcumin. It also addresses investment trends, such as the $6.2 million Series A funding round by a U.S. biotech firm developing DHM-based pharmaceuticals.